Understanding the new and evolving profile of adverse drug effects in schizophrenia

This publication has 108 references indexed in Scilit:

• Obesity
  New England Journal of Medicine, 2002
• Risk of adverse events associated with antipsychotic treatment — Results from the Canadian national outcomes measurement study in schizophrenia
  European Neuropsychopharmacology, 2001
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• The Apparent Effects of Ziprasidone on Plasma Lipids and Glucose
  The Journal of Clinical Psychiatry, 2001
• Psychopharmacology: Cardiac Effects of Antipsychotic Medications
  Psychiatric Services, 2001
• Effects of obesity on QT, RR, and QTc intervals
  The American Journal of Cardiology, 1995
• Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors
  Nature, 1995
• Hyperglycemic properties of serotonin receptor antagonists
  Life Sciences, 1991
• Weight Gain Associated With Psychotropic Drugs
  Southern Medical Journal, 1989
• An Open Clinical Trial of Fenfluramine in Chronic Schizophrenia: A Pilot Study
  International Clinical Psychopharmacology, 1987